ALTASCIENCES
9.12.2021 17:02:06 CET | Business Wire | Press release
Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection.
The first of several clinical trials to characterize XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors, its purpose is to determine whether the increased bioavailability of oxypurinol demonstrated for this formulation in preclinical studies will be replicated in humans.
Dr. Allen Davidoff, President and CEO stated, “XORTX is pleased to be starting work with Altasciences as we initiate the characterization of our novel, proprietary formulations of xanthine oxidase inhibitors. This study marks the first of several clinical trials planned for the next year and an exciting opportunity to advance our kidney disease programs through preliminary characterization, followed by late stage registration trials. ”
“With a pressing need for better therapeutic options and a global prevalence of kidney disease, we are proud to partner with XORTX for such an important study. We look forward to supporting this innovative company in their goal of bringing a valuable new treatment to the next stage, and getting better drugs to the people who need them, faster, ” stated Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences.
Altasciences offers a seamless drug development solution that allows sponsors to work with a single, integrated CRO/CDMO in support of early-phase research, from lead candidate selection to preclinical testing to clinical proof of concept in the most time- and cost-efficient way possible.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005134/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexo Championship Returns to Aberdeenshire as Nexo Expands DP World Tour Footprint20.5.2026 16:00:00 CEST | Press release
Nexo renews its Nexo Championship title partnership for the second year in 2026. The Nexo Championship, with a newly increased prize fund of $3 million, will return to Aberdeenshire on August 20-23, 2026. The tournament concludes the 2026 Closing Swing on the Race to Dubai schedule. Nexo, the premier digital assets wealth platform, and the DP World Tour have confirmed a renewed agreement that will see the Nexo Championship return to Trump International Golf Links in Aberdeenshire from August 20-23, 2026. The tournament will serve as the concluding event of the DP World Tour’s Closing Swing – the final event of the first phase of the 2026 Race to Dubai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520684059/en/ Nexo Championship 2026 In 2025, Nexo joined the DP World Tour as its Official Digital Wealth Platform through 2027 before soon adding the title rights at the Nexo Championship. For its part, the Nexo Championship
Visa Threats Report: As Network Security Strengthens, Criminals Accelerate Shift to AI-Enabled Social Engineering20.5.2026 15:16:00 CEST | Press release
Spring 2026 Biannual Threats Report shows how strengthening payment security is pushing criminals toward AI-enabled social engineering Visa (NYSE: V), a world leader in digital payments, today released its Spring 2026 Biannual Threats Report, revealing that scams have become the fastest-growing source of consumer harm as criminals increasingly use artificial intelligence and social engineering to manipulate people into authorizing payments themselves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520153924/en/ The report draws on intelligence from Visa’s global network and underscores a critical shift in the fraud landscape: while core payment security continues to strengthen at the network level, criminals are redirecting their efforts away from technical system compromises toward exploiting human trust. From July to December 2025, Visa identified nearly $1 billion in scam-related activity, making scams the single large
1GLOBAL Launches Verint Communications Analytics to Enhance Cloud Compliance for Financial and Regulated Industries20.5.2026 15:00:00 CEST | Press release
1GLOBAL now offers transcription with insights into mobile calls in 10 countries on Verint Communications Analytics, built specifically for financial markets and trading environmentsStreamlines the compliance investigation and mobile call monitoring process through transcription and analysisSupports transcription and translation from 30+ languages into English with near real-time processing 1GLOBAL, a pioneer in global telecommunications solutions, today announced its launch of Verint® Communications Analytics, a key offering within Verint Financial Compliance (VFC) providing mobile call transcription and analytics capabilities. Verint Communications Analytics has been designed to help financial institutions and regulated organizations accelerate productivity when monitoring voice calls (including mobile), identifying behavioral patterns, querying data intentionally by topic, risks, keywords or sentiment, identifying misuse and reducing regulatory risk. Verint Communications Analytics
Xsolla Expands Nordic Presence With Industry Engagements Across Sweden, Including Official Sponsorship of Nordic Game 202620.5.2026 15:00:00 CEST | Press release
Coordinated Activations Across Sweden Underscore Xsolla’s Continued Investment In The Nordic Games Ecosystem, Bringing Developers, Partners, And Creators Together Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announces a comprehensive program of events and activations across Sweden throughout May 2026, including its official sponsorship of Nordic Game 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520833786/en/ Graphic: Xsolla At Nordic Game, Xsolla will showcase its Web Shop solution, a direct-to-consumer (D2C) platform designed to help developers build and scale their own storefronts outside traditional app stores. The Web Shop ecosystem integrates storefronts, LiveOps tools, and player engagement features, enabling studios to strengthen player relationships while increasing revenue and operational control. Xsolla will also highlight its global pay
Cyclic Materials Appoints Former Siemens and Alcoa CEO Klaus Kleinfeld to Board of Directors20.5.2026 14:30:00 CEST | Press release
Dr. Klaus Kleinfeld’s proven leadership at two Fortune 500 public companies will strengthen the company’s global expansion Cyclic Materials, the rare earth recycling company enabling domestic circular supply chain for critical materials around the world, today announced the appointment of Dr. Klaus Kleinfeld to its Board of Directors. Dr. Kleinfeld brings decades of experience leading global industrial and advanced manufacturing businesses, including serving as CEO of two Fortune 500 companies – Siemens AG and Alcoa. His experience growing complex international operations, navigating global markets, and leading large industrial transformations will support Cyclic Materials’ industrial expansion to meet an accelerating global demand. An internationally recognized executive, investor, and entrepreneur, Dr. Kleinfeld has advised multiple U.S. Presidents and global leaders on industrial competitiveness, technology, and economic development. “Cyclic Materials is scaling a strategically vita
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom